several pharmaceutical companies were involved in the development of anti-CD47 antibodies for potential therapeutic use. Please note that the landscape of pharmaceutical development is continually evolving, and new companies or partnerships may have emerged since then.
Some of the companies that were known to be working on anti-CD47 antibody programs included:
Forty Seven Inc. (acquired by Gilead Sciences in 2020): This company was a frontrunner in anti-CD47 therapy development and was actively working on Magrolimab (formerly known as 5F9), an anti-CD47 antibody.
Trillium Therapeutics Inc.: Trillium Therapeutics was also developing an anti-CD47 antibody called TTI-622.
I-Mab: This biopharmaceutical company based in China was involved in the development of an anti-CD47 antibody known as TJC4.
Alector: While primarily focused on immuno-neurology, Alector has been working on a portfolio of immuno-oncology programs, including anti-CD47 antibodies.
Alexo Therapeutics: Alexo Therapeutics was another company actively researching and developing anti-CD47 antibodies.
It is essential to consult more recent sources or official company websites to get the most up-to-date information on the current status of anti-CD47 antibody development and the companies involved. Clinical trials and partnerships can significantly impact the landscape of pharmaceutical development in the biotechnology and pharmaceutical industries.